Key result
Transcatheter aortic valve implantation is being evaluated as an alternative to surgical aortic valve replacement in low- to intermediate-risk patients with severe aortic stenosis.
Why the study?
With TAVI established in high-risk patients and expanding to intermediate-risk subjects, the role of TAVI in low-risk patients required examination.
Does transcatheter aortic valve implantation (TAVI) provide advantages over surgical aortic valve replacement (SAVR) in low- to intermediate-risk patients with symptomatic severe aortic stenosis?
Does transcatheter aortic valve implantation (TAVI) provide advantages over surgical aortic valve replacement (SAVR) in low- to intermediate-risk patients with symptomatic severe aortic stenosis?
Answers are grounded in this paper and cite their sources.
This review highlights the expanding role of TAVI into lower-risk populations with severe aortic stenosis, discussing potential advantages and challenges.
In the last decade, transcatheter aortic valve implantation (TAVI), a disruptive technology, has revolutionized the therapy of symptomatic severe aortic stenosis, and current guidelines state that the recommendations for TAVI and surgical aortic valve replacement (SAVR) are equivalent in patients at high-risk. Increased operator experience, technical advances in the new generation of transcatheter heart valves (THV) and excellent TAVI results in recently published randomized controlled trials have led to the expansion of TAVI indication as an alternative to SAVR in intermediate-risk subjects, given appropriate patient selection. The time is opportune to examine the role of TAVI in low-risk patients, currently the objective of on-going randomized trials. This review aims to summarize the available knowledge on TAVI in low- to intermediate-risk patients and to discuss the potential advantages and pitfalls TAVI will face in this clinical setting.
No takes yet. Share an insight, caveat, or question.
Tarantini et al. (2017) conducted a review in Symptomatic severe aortic stenosis. Transcatheter aortic valve implantation (TAVI) vs. Surgical aortic valve replacement (SAVR) was evaluated. Transcatheter aortic valve implantation is being evaluated as an alternative to surgical aortic valve replacement in low- to intermediate-risk patients with severe aortic stenosis.
Synapse has enriched 10 related papers. Consider them for comparative context: